It is being explored the use of target therapy in these situations, favored by the durable partial response of a patient with Mucoepidermoid lung carcinoma with an alteration of EGFR treated with gefinitib (16). This evidence concerns the gene EGFR and pulmonary mucoepidermoid carcinoma.